Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. PRIM
3. DPZ
4. ACN
5. DFTX
6. IBM
7. META
8. AISP
9. KFY
10. SPY

Go back to Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates

Arcturus Therapeutics (ARCT) Tops Q4 EPS by 12c

March 1, 2021 4:16 PM EST

Arcturus Therapeutics (NASDAQ: ARCT) reported Q4 EPS of ($0.76), $0.12 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $2.97 million versus the consensus estimate of $2.36 million.

Based on highly promising clinical data from our Phase 1/2 study and emerging mRNA vaccine immunological data, we are advancing ARCT-021 for further... More